These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8119066)

  • 21. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing sample size formulae for trials with unbalanced allocation using the logrank test.
    Hsieh FY
    Stat Med; 1992 Jun; 11(8):1091-8. PubMed ID: 1496196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of overviews of randomized trials.
    Hennekens CH; Buring JE; Hebert PR
    Stat Med; 1987; 6(3):397-409. PubMed ID: 3616292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
    Sevdalis N; Jacklin R
    J Eval Clin Pract; 2008 Oct; 14(5):919-22. PubMed ID: 18373582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial outcome in neuropathic pain: relationship to study characteristics.
    Katz J; Finnerup NB; Dworkin RH
    Neurology; 2008 Jan; 70(4):263-72. PubMed ID: 17914067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the power of two tests for qualitative interactions.
    Piantadosi S; Gail MH
    Stat Med; 1993 Jul; 12(13):1239-48. PubMed ID: 8210823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012.
    Vaduganathan M; Patel RB; Samman-Tahhan A; Kalogeropoulos AP; Georgiopoulou VV; Fonarow GC; Gheorghiade M; Butler J
    Int J Cardiol; 2016 Jul; 214():16-8. PubMed ID: 27055160
    [No Abstract]   [Full Text] [Related]  

  • 28. Testing for qualitative interactions between stages in an adaptive study.
    Parker RA
    Stat Med; 2010 Jan; 29(2):210-8. PubMed ID: 19908261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What conditions are necessary to assess antidepressant efficacy?
    Quitkin FM; Klein DF
    Arch Gen Psychiatry; 2000 Apr; 57(4):323-4. PubMed ID: 10768690
    [No Abstract]   [Full Text] [Related]  

  • 30. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
    King TE; Albera C; Bradford WZ; Costabel U; du Bois RM; Leff JA; Nathan SD; Sahn SA; Valeyre D; Noble PW
    Am J Respir Crit Care Med; 2014 Apr; 189(7):825-31. PubMed ID: 24476390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size and screening size trade-off in the presence of subgroups with different expected treatment effects.
    Rudser KD; Bendert E; Koopmeiners JS
    J Biopharm Stat; 2014; 24(2):344-58. PubMed ID: 24605973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints.
    Natarajan R; Turnbull BW; Slate EH; Clark LC
    Comput Methods Programs Biomed; 1996 Mar; 49(2):137-47. PubMed ID: 8735021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. More reliable outcome measures can reduce sample size requirements.
    Leon AC; Marzuk PM; Portera L
    Arch Gen Psychiatry; 1995 Oct; 52(10):867-71. PubMed ID: 7575107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design.
    Hammami MM; Hammami S; Al-Swayeh R; Al-Gaai E; Farah FA; De Padua SJ
    BMC Med Res Methodol; 2016 Nov; 16(1):166. PubMed ID: 27899067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the effect of the run-in on the power of the Physicians' Health Study.
    Lang JM; Buring JE; Rosner B; Cook N; Hennekens CH
    Stat Med; 1991 Oct; 10(10):1585-93. PubMed ID: 1947514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conducting clinical trials to establish drug efficacy in chronic pain.
    Harden RN; Bruehl S
    Am J Phys Med Rehabil; 2001 Jul; 80(7):547-57. PubMed ID: 11421526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016.
    Khan A; Fahl Mar K; Schilling J; Brown WA
    PLoS One; 2018; 13(2):e0193043. PubMed ID: 29489874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acupuncture for the relief of cancer-related pain--a systematic review.
    Lee H; Schmidt K; Ernst E
    Eur J Pain; 2005 Aug; 9(4):437-44. PubMed ID: 15979024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factorial designs: an overview with applications to orthodontic clinical trials.
    Pandis N; Walsh T; Polychronopoulou A; Katsaros C; Eliades T
    Eur J Orthod; 2014 Jun; 36(3):314-20. PubMed ID: 23885023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.